Idebenone - Chiesi Farmaceutici/Santhera Pharmaceuticals
Alternative Names: Catena; CV-2619; Puldysa; Raxone; SNTMC17; SovrimaLatest Information Update: 05 Nov 2023
At a glance
- Originator Santhera Pharmaceuticals
- Developer Columbia University; National Institute of Neurological Disorders and Stroke; Santhera Pharmaceuticals; Takeda
- Class Benzoquinones; Coenzymes; Eye disorder therapies; Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Antioxidants; Electron transport chain complex protein modulators; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Leber's hereditary optic atrophy
- Phase II Multiple sclerosis
- Suspended Friedreich's ataxia
- No development reported MELAS syndrome
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 31 Jul 2023 Chiesi Farmaceutici acquires idebenone from Santhera Pharmaceuticals
- 29 Nov 2022 No development reported - Preregistration for Leber's hereditary optic atrophy in South Korea (PO)
- 25 Oct 2021 Santhera completes a phase III IONIA-E trial in Friedreich's ataxia (In adolescents, In children) in USA